title: Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.
abstract: OBJECTIVE
  Amyloid-beta (Aβ) peptide is reported to initiate flexible inflammation in the hippocampus of the human brain in Alzheimer's disease (AD). The present study aimed to investigate the possible effects of atorvastatin on the production of inflammation cytokines in the hippocampus and the potential impacts on behavioral ability, in an AD model.
  
  
  METHODS
  We firstly established AD rat models using intracerebroventricular injection of Aβ1-42. A Morris water maze was also performed to determine the spatial learning and memory ability in the AD models. Intracellular staining of interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha was determined using immunohistochemical staining at 6 hours and day 7 after the injection of Aβ.
  
  
  RESULTS
  The escape latency of the atorvastatin-treated AD group (5 mg/kg/d) was significantly shorter than that of AD group on day 3 (41 ± 1.05 seconds versus 47 ± 1.05 seconds, P < 0.01) and day 4 (34 ± 1.25 seconds versus 43 ± 1.01 seconds, P < 0.01) after the beginning of the training. Furthermore, the atorvastatin-treated AD group displayed a significant higher mean number of annulus crossings than did the AD group (2.9 ± 0.5 versus 2.4 ± 0.9, P < 0.05). Fewer injured nerve cells and proliferated glial cells were also demonstrated in the atorvastatin-treated AD group than in the AD group. Of great importance, we demonstrated that IL-1β, IL-6, and tumor necrosis factor alpha were significantly decreased in the atorvastatin-treated AD group than that in the AD group.
  
  
  CONCLUSIONS
  Atorvastatin might attenuate the damage of nerve cells and improve learning and memory ability by inhibiting inflammatory response in the progression of AD.
authors: Department of Neurology, Jinan Central Hospital affiliated to Shandong University, Jinan, People's Republic of China.
authors: Yuan-Yuan
authors: YY
authors: Zhang
authors: Yu-Chen
authors: YC
authors: Fan
authors: Min
authors: M
authors: Wang
authors: Dong
authors: D
authors: Wang
authors: Xiao-Hong
authors: XH
authors: Li
mesh_terms: D000544:Alzheimer Disease / Q000139:chemically induced / Q000188:drug therapy*; D016229:Amyloid beta-Peptides / Q000008:administration & dosage; D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069059:Atorvastatin; D004195:Disease Models, Animal; D006538:Heptanoic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D006624:Hippocampus / Q000378:metabolism*; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors*; D053583:Interleukin-1beta / Q000037:antagonists & inhibitors; D008297:Male; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000093242:Interleukin-6 Inhibitors
chemical_list: D016229:Amyloid beta-Peptides; D000924:Anticholesteremic Agents; D000069059:Atorvastatin; D006538:Heptanoic Acids; D018836:Inflammation Mediators; D053583:Interleukin-1beta; D011758:Pyrroles; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors
keywords: amyloid-beta; inflammation; interleukin-1β; interleukin-6; tumor necrosis factor
references: Biochem J. 2006 Oct 15;399(2):205-14
references: 16803455
references: Arch Neurol. 2002 Feb;59(2):223-7
references: 11843693
references: Nature. 2009 Oct 15;461(7266):895-7
references: 19829367
references: J Alzheimers Dis. 2001 Apr;3(2):221-229
references: 12214063
references: J Neurochem. 2009 Dec;111(6):1275-308
references: 20050287
references: J Neurosci. 2005 Feb 2;25(5):1203-10
references: 15689557
references: Biol Psychiatry. 2010 Nov 15;68(10):930-41
references: 20692646
references: J Neurochem. 2000 Mar;74(3):1017-25
references: 10693932
references: J Neurosci. 2002 Jul 15;22(14):5900-9
references: 12122052
references: Curr Opin Investig Drugs. 2009 Jan;10(1):46-55
references: 19127486
references: J Biol Chem. 2005 May 13;280(19):18755-70
references: 15718241
references: J Neuropathol Exp Neurol. 2009 Mar;68(3):314-25
references: 19225406
references: Inflamm Res. 2002 Feb;51(2):58-62
references: 11926313
references: J Am Coll Cardiol. 1999 Jan;33(1):234-41
references: 9935036
references: J Mol Neurosci. 2002 Aug-Oct;19(1-2):155-61
references: 12212773
references: Cardiovasc Drugs Ther. 2001;15(3):211-8
references: 11713888
references: Neurobiol Dis. 2005 Apr;18(3):459-65
references: 15755672
references: Biochim Biophys Acta. 2010 Aug;1801(8):860-7
references: 20303415
references: Neurology. 2000 Feb 22;54(4):790-6
references: 10690964
references: Nature. 2002 Nov 7;420(6911):78-84
references: 12422218
references: Behav Brain Res. 2004 Dec 6;155(2):185-96
references: 15364477
references: Drugs. 2007;67(1):11-6
references: 17209661
references: J Cell Mol Med. 2007 May-Jun;11(3):383-92
references: 17635634
references: Dement Geriatr Cogn Disord. 2009;27(6):519-24
references: 19478483
references: J Neurosci. 2003 Oct 29;23(30):9796-804
references: 14586007
references: Arch Neurol. 2000 Oct;57(10):1439-43
references: 11030795
references: Fundam Appl Toxicol. 1996 Aug;32(2):285-92
references: 8921332
references: Neurobiol Dis. 2001 Oct;8(5):890-9
references: 11592856
references: Eur J Neurosci. 2001 Aug;14(3):474-82
references: 11553297
references: J Leukoc Biol. 2001 Jun;69(6):959-62
references: 11404382
references: Exp Neurol. 2010 Jun;223(2):282-93
references: 19782682
references: J Neurosci. 2003 Dec 3;23(35):11104-11
references: 14657168
references: Neurobiol Dis. 2001 Dec;8(6):1094-101
references: 11741404
references: Proc Natl Acad Sci U S A. 2001 May 8;98(10):5856-61
references: 11296263
references: J Neurosci. 2000 Jan 15;20(2):558-67
references: 10632585
references: J Clin Pharm Ther. 2004 Jun;29(3):209-13
references: 15153082